Tags

Type your tag names separated by a space and hit enter

Dual time point FDG-PET/CT imaging... Potential tool for diagnosis of breast cancer.
Clin Radiol. 2008 Nov; 63(11):1213-27.CR

Abstract

AIM

This prospective study was designed to assess the utility of the dual time point imaging technique using 2-[(18)F]-fluoro-2-deoxy-D-glucose (FDG) positron-emission tomography/computed tomography (PET/CT) to detect primary breast cancer and to determine whether it is useful for the detection of small and non-invasive cancers, as well as cancers in dense breast tissue.

METHODS

One hundred and eleven patients with newly diagnosed breast cancer underwent two sequential PET/CT examinations (dual time point imaging) for preoperative staging. The maximum standardized uptake value (SUVmax) of FDG was measured from both time points. The percentage change in SUVmax (DeltaSUVmax%) between time points 1 (SUVmax1) and 2 (SUVmax2) was calculated. The patients were divided into groups: invasive (n=82), non invasive (n=29); large (>10mm; n=80), small (<or=10mm; n=31); tumours in dense breasts (n=61), and tumours in non-dense breasts (n=50). The tumour:background (T:B) ratios at both time points were measured and the DeltaSUVmax%, DeltaT:B% values were calculated. All PET study results were correlated with the histopathology results.

RESULTS

Of the 111 cancer lesions, 88 (79.3%) showed an increase and 23 (20.7%) showed either no change [10 (9%)] or a decrease [13 (11.7%)] in the SUVmax over time. Of the 111 contralateral normal breasts, nine (8.1%) showed an increase and 102 (91.9%) showed either no change [17 (15.3%)] or a decrease [85 (76.6%)] in the SUVmax over time. The mean+/-SD of SUVmax1, SUVmax2, Delta%SUVmax were 4.9+/-3.6, 6.0+/-4.5, and 22.6+/-13.1% for invasive cancers, 4.1+/-3.8, 4.4+/-4.8, and -2.4+/-18.5% for non-invasive cancers, 2.3+/-1.9, 2.7+/-2.3, and 12.9+/-21.1% for small cancers, 5.6+/-3.7, 6.8+/-4.8, and 17.3+/-17.1% for large cancers, 4.9+/-3.7, 5.8+/-4.8, and 15.1+/-17.6% for cancers in dense breast, and 4.5+/-3.6, 5.4+/-4.5, and 17.2+/-19.2% for cancers in non-dense breast. The receiver-operating characteristic (ROC) analysis suggested DeltaSUVmax% of 8% as the only significant cut-off for discrimination between invasive and non-invasive cancer (sensitivity 84.1%, specificity 75.9%, p<0.0001).

CONCLUSION

Dual time point FDG-PET/CT improves the discrimination between non-invasive and invasive cancers, and provided superior sensitivity for the detection of small cancers and cancers in dense breast.

Authors+Show Affiliations

Radiology Department, Faculty of Medicine, Menoufiya University School of Medicine, Egypt. ashradio@gmail.comNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Evaluation Study
Journal Article

Language

eng

PubMed ID

18929039

Citation

Zytoon, A A., et al. "Dual Time Point FDG-PET/CT Imaging... Potential Tool for Diagnosis of Breast Cancer." Clinical Radiology, vol. 63, no. 11, 2008, pp. 1213-27.
Zytoon AA, Murakami K, El-Kholy MR, et al. Dual time point FDG-PET/CT imaging... Potential tool for diagnosis of breast cancer. Clin Radiol. 2008;63(11):1213-27.
Zytoon, A. A., Murakami, K., El-Kholy, M. R., & El-Shorbagy, E. (2008). Dual time point FDG-PET/CT imaging... Potential tool for diagnosis of breast cancer. Clinical Radiology, 63(11), 1213-27. https://doi.org/10.1016/j.crad.2008.03.014
Zytoon AA, et al. Dual Time Point FDG-PET/CT Imaging... Potential Tool for Diagnosis of Breast Cancer. Clin Radiol. 2008;63(11):1213-27. PubMed PMID: 18929039.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Dual time point FDG-PET/CT imaging... Potential tool for diagnosis of breast cancer. AU - Zytoon,A A, AU - Murakami,K, AU - El-Kholy,M R, AU - El-Shorbagy,E, Y1 - 2008/09/14/ PY - 2007/09/13/received PY - 2008/03/01/revised PY - 2008/03/14/accepted PY - 2008/10/22/pubmed PY - 2008/12/17/medline PY - 2008/10/22/entrez SP - 1213 EP - 27 JF - Clinical radiology JO - Clin Radiol VL - 63 IS - 11 N2 - AIM: This prospective study was designed to assess the utility of the dual time point imaging technique using 2-[(18)F]-fluoro-2-deoxy-D-glucose (FDG) positron-emission tomography/computed tomography (PET/CT) to detect primary breast cancer and to determine whether it is useful for the detection of small and non-invasive cancers, as well as cancers in dense breast tissue. METHODS: One hundred and eleven patients with newly diagnosed breast cancer underwent two sequential PET/CT examinations (dual time point imaging) for preoperative staging. The maximum standardized uptake value (SUVmax) of FDG was measured from both time points. The percentage change in SUVmax (DeltaSUVmax%) between time points 1 (SUVmax1) and 2 (SUVmax2) was calculated. The patients were divided into groups: invasive (n=82), non invasive (n=29); large (>10mm; n=80), small (<or=10mm; n=31); tumours in dense breasts (n=61), and tumours in non-dense breasts (n=50). The tumour:background (T:B) ratios at both time points were measured and the DeltaSUVmax%, DeltaT:B% values were calculated. All PET study results were correlated with the histopathology results. RESULTS: Of the 111 cancer lesions, 88 (79.3%) showed an increase and 23 (20.7%) showed either no change [10 (9%)] or a decrease [13 (11.7%)] in the SUVmax over time. Of the 111 contralateral normal breasts, nine (8.1%) showed an increase and 102 (91.9%) showed either no change [17 (15.3%)] or a decrease [85 (76.6%)] in the SUVmax over time. The mean+/-SD of SUVmax1, SUVmax2, Delta%SUVmax were 4.9+/-3.6, 6.0+/-4.5, and 22.6+/-13.1% for invasive cancers, 4.1+/-3.8, 4.4+/-4.8, and -2.4+/-18.5% for non-invasive cancers, 2.3+/-1.9, 2.7+/-2.3, and 12.9+/-21.1% for small cancers, 5.6+/-3.7, 6.8+/-4.8, and 17.3+/-17.1% for large cancers, 4.9+/-3.7, 5.8+/-4.8, and 15.1+/-17.6% for cancers in dense breast, and 4.5+/-3.6, 5.4+/-4.5, and 17.2+/-19.2% for cancers in non-dense breast. The receiver-operating characteristic (ROC) analysis suggested DeltaSUVmax% of 8% as the only significant cut-off for discrimination between invasive and non-invasive cancer (sensitivity 84.1%, specificity 75.9%, p<0.0001). CONCLUSION: Dual time point FDG-PET/CT improves the discrimination between non-invasive and invasive cancers, and provided superior sensitivity for the detection of small cancers and cancers in dense breast. SN - 1365-229X UR - https://www.unboundmedicine.com/medline/citation/18929039/Dual_time_point_FDG_PET/CT_imaging____Potential_tool_for_diagnosis_of_breast_cancer_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0009-9260(08)00253-5 DB - PRIME DP - Unbound Medicine ER -